<DOC>
	<DOCNO>NCT00002118</DOCNO>
	<brief_summary>To allow , compassionate use basis , zalcitabine ( ddC ) pediatric patient symptomatic HIV disease fail treatment intolerant zidovudine ( AZT ) , complete ddC protocol , ineligible ongoing clinical trial .</brief_summary>
	<brief_title>An Open-Label Safety Program Use Zalcitabine ( Dideoxycytidine ; ddC ) Pediatric Patients With Symptomatic HIV Infection Who Have Failed Are Intolerant AZT Monotherapy , Who Have Completed Other ddC Protocols , Are Ineligible Other Ongoing Clinical Studies</brief_title>
	<detailed_description>Patients receive ddC evaluate study entry every 3 month thereafter , 3 month ddC becomes approve pediatric patient sponsor deems necessary terminate protocol .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<criteria>Inclusion Criteria Patients must : Symptomatic HIV infection . Failure intolerance AZT monotherapy OR complete ddC protocol OR ineligible ongoing clinical trial . Consent parent guardian require . Note : Patients meet eligibility requirement may discuss case medical monitor .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>August 1997</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>